title: Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD.
abstract: OBJECTIVE
  Adipokines are protein mediators first described as products of adipose tissue regulating energy metabolism and appetite. Recently, adipokines have also been found to modulate inflammation and smooth muscle cell responses. Therefore we investigated the association of two adipokines, adiponectin and leptin, with the degree of emphysema, pulmonary function, symptoms and glucocorticoid responsiveness in patients with COPD.
  
  
  METHODS
  Plasma adiponectin and leptin levels, spirometry, body plethysmography and symptoms were measured in 43 male COPD patients with smoking history ≥ 20 pack-years, post bronchodilator FEV1/FVC < 0.7 and pulmonary emphysema on HRCT. The measurements were repeated in a subgroup of patients after 4 weeks' treatment with inhaled fluticasone.
  
  
  RESULTS
  In patients with COPD, plasma adiponectin levels correlated positively with airway resistance (Raw) (r = 0.362, p = 0.019) and functional residual capacity (FRC) (r = 0.355, p = 0.046). Furthermore, the baseline adiponectin concentration correlated negatively with the fluticasone induced changes in St George's Respiratory questionnaire (SGRQ) symptom score (r = -0.413, p = 0.040) and in FRC % pred (r = -0.428, p = 0.003), i.e. a higher baseline plasma adiponectin level was associated with more pronounced alleviation of symptoms and dynamic hyperinflation. Plasma leptin levels were not related to the measures of lung function, symptoms or glucocorticoid responsiveness.
  
  
  CONCLUSIONS
  Plasma adiponectin levels were associated with peripheral airway obstruction and dynamic hyperinflation in patients with COPD. A higher adiponectin level predicted more favourable relief of symptoms and hyperinflation during glucocorticoid treatment. Adiponectin may have a role in the COPD pathogenesis; it may also be a biomarker of disease severity and treatment responses in this disease.
authors.affiliation: Department of Respiratory Medicine, Tampere University Hospital, PL 2000, 33521 Tampere, Finland; The Immunopharmacology Research Group, University of Tampere School of Medicine, Tampere University Hospital, 33014 University of Tampere, Finland. Electronic address: sirpa.leivo-korpela@uta.fi.
authors.forename: Sirpa
authors.initials: S
authors.lastname: Leivo-Korpela
authors.affiliation: Allergy Centre, Tampere University Hospital, PL 2000, 33521 Tampere, Finland; The Immunopharmacology Research Group, University of Tampere School of Medicine, Tampere University Hospital, 33014 University of Tampere, Finland.
authors.forename: Lauri
authors.initials: L
authors.lastname: Lehtimäki
authors.affiliation: The Immunopharmacology Research Group, University of Tampere School of Medicine, Tampere University Hospital, 33014 University of Tampere, Finland.
authors.forename: Katriina
authors.initials: K
authors.lastname: Vuolteenaho
authors.affiliation: The Immunopharmacology Research Group, University of Tampere School of Medicine, Tampere University Hospital, 33014 University of Tampere, Finland.
authors.forename: Riina
authors.initials: R
authors.lastname: Nieminen
authors.affiliation: Department of Radiology, Tampere University Hospital, PL 2000, 33521 Tampere, Finland.
authors.forename: Lea
authors.initials: L
authors.lastname: Kööbi
authors.affiliation: Department of Radiology, Tampere University Hospital, PL 2000, 33521 Tampere, Finland.
authors.forename: Ritva
authors.initials: R
authors.lastname: Järvenpää
authors.affiliation: The Immunopharmacology Research Group, University of Tampere School of Medicine, Tampere University Hospital, 33014 University of Tampere, Finland; Department of Respiratory Medicine, Seinäjoki Central Hospital, 60220 Seinäjoki, Finland.
authors.forename: Hannu
authors.initials: H
authors.lastname: Kankaanranta
authors.affiliation: Department of Respiratory Medicine, Tampere University Hospital, PL 2000, 33521 Tampere, Finland.
authors.forename: Seppo
authors.initials: S
authors.lastname: Saarelainen
authors.affiliation: The Immunopharmacology Research Group, University of Tampere School of Medicine, Tampere University Hospital, 33014 University of Tampere, Finland.
authors.forename: Eeva
authors.initials: E
authors.lastname: Moilanen
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000273:Adipose Tissue / Q000503:physiopathology; D000280:Administration, Inhalation; D000730:Androstadienes / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000068298:Fluticasone; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D020738:Leptin / Q000097:blood*; D008297:Male; D010993:Plethysmography, Whole Body; D011237:Predictive Value of Tests; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D012907:Smoking / Q000009:adverse effects; D013147:Spirometry; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D052242:Adiponectin; D000730:Androstadienes; D015415:Biomarkers; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D020738:Leptin; D000068298:Fluticasone
keywords: Adipokines; Adiponectin; Chronic obstructive pulmonary disease (COPD); Glucocorticoid; Leptin; Pulmonary emphysema